Projected Growth of Single-Molecule Real-Time Sequencing Market to Reach $5.32 Billion by 2030

The Escalating Potential of Single-molecule Real-time (SMRT) Sequencing

The Single-molecule Real-time (SMRT) Sequencing market is on track for remarkable growth, with estimates suggesting it will expand from USD 2.92 billion in 2025 to a staggering USD 5.32 billion by 2030. This represents a Compound Annual Growth Rate (CAGR) of 12.8% during the forecast period.

Market Dynamics and Trends

In North America, there is an accelerating trend as laboratories, hospitals, and genome centers increasingly turn towards long-read data to drive solutions for complex problems, such as rare-disease diagnosis and intricate cancer genomic studies. Supported by significant public funding and collaborations among universities, consortia, and corporate entities, the North American market is becoming a dynamic hub for SMRT technology.

The market is divided into products and services, with the product segment commanding the major share due to the fundamental nature of instruments, consumables, and bioinformatics tools necessary for sequencing runs. As the demand for whole-genome, transcriptome, and epigenetics projects increases, the continual improvement in throughput and read accuracy drives laboratories to adopt new SMRT platforms.

Revenue Segmentation by Workflow

This sector can also be segmented by workflow: pre-sequencing, sequencing, and data analysis. The sequencing step dominated the financial allotments, indicating that most expenses are associated with acquiring high-value instruments and consumables necessary for generating high-fidelity long-read data that is critical for extensive genomic investigations. To accommodate a shift from targeted projects to large-scale studies, the growing need for throughput and accuracy further emphasizes the crucial role of sequencing.

Innovations in SMRT Sequencing

Emerging innovations are catalyzing a transformation in single-molecule real-time sequencing. The advent of high-throughput instruments, advanced AI-based base-calling systems, and improved integration of long-read and short-read platforms are expediting the process of whole-genome and multi-omics data collection, becoming both faster and more cost-effective. Moreover, the regulatory demand for high-quality and accurately traceable genomic data drives laboratories to implement fully automated SMRT sequencing pipelines that support diverse research and clinical applications.

Academic Research Dominance

In 2024, academic research institutes constituted the largest consumer segment within the SMRT sequencing marketplace. Their prominence stems from the increased utilization of long-read sequencing capabilities to tackle challenging projects, including de novo genome assembly, structural variant mapping, and full-length transcript sequencing. This application supports functional genomics and method development, solidifying their significant role in the market.

Promising Growth in Asia Pacific

The Asia Pacific region is anticipated to emerge as the fastest-growing segment within the SMRT sequencing market in the upcoming years. This growth surge is propelled by enhanced investments in genomics, expanding genome centers, and the establishment of advanced clinical laboratories. The growing focus on rare disease testing and complex cancer studies further enhances the appeal of long-read sequencing in this region.

Key Players in the Market

Leading companies influencing the SMRT sequencing landscape include Pac Bio, Eurofins Scientific, Illumina, Thermo Fisher, Agilent Technologies, and BGI Group, among others. Their innovations and contributions continue to shape the evolution of genomic research.

Conclusion

As the single-molecule real-time sequencing market evolves, it is set to empower expansive research and clinical applications, contributing significantly to advancements in genomic studies and enabling researchers to rapidly push the boundaries of modern science. The continuous investment, along with technological advancements, promises a bright future for SMRT sequencing well into 2030 and beyond.